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Abstract
Despite the expression of a myriad of virulence factors, healthy individuals are generally able to resist
infections with Pseudomonas aeruginosa. Polymorphonuclear leukocyte-dependent killing is the major
mechanism responsible for resistance; dysregulation of host defense mechanisms in addition to
expression of specific bacterial factors can result in life-threatening infections with this bacterium.
Introduction and context
Polymorphonuclear leukocytes (PMNs) (neutrophils) are
phagocyticcellsthatareabletokillpathogens;elimination
by these cells is a major innate host defense mechanism.
In the case of healthy individuals, this host defense
mechanism is usually effective at removing Pseudomonas
aeruginosa. However, in hospitalized patients, particularly
those withcompromised immune systems,thisbacterium
is a major cause of morbidity and mortality. It is also
the leading bacterial cause of acute ventilator-associated
pneumonia and chronic lung infections in patients with
cystic fibrosis (CF). Defining the dysfunction of neutro-
phils in susceptible individuals provides the basis for
understanding normal host responses to P. aeruginosa.
Furthermore, recognition of bacterial factors that promote
resistance to PMN killing may help identify therapeutic
targets for this important opportunistic pathogen.
Major recent advances
The breakdown of normal innate immune function
results in increased susceptibility to P. aeruginosa.U n l e s s
there is compromise, either at a mucosal surface or by
immune defects, healthy humans are generally able to
resist becoming infected with this bacterium. Patients
undergoing chemotherapy are particularly susceptible to
P. aeruginosa, which can lead to life-threatening pneumo-
nia and bacteremia. Mice have been used as a model
organism for this type of compromise: treatment with the
chemotherapeutic agent, cyclophosphamide (Cy) or an
antibody generally specific for neutrophils, RB6-8C5 (also
known as anti-Gr1), results in mice that are considered
leukopenic or neutropenic, respectively. A lethal infection
of these immunocompromised mice can be achieved by
intranasaladministrationofadoseofbacteriathatismore
than 6 logs lower than that needed to cause a similar
infection in mice with intact immune function [1]. The
P. aeruginosa strain used in these studies did not contain
the cytotoxic phospholipase, ExoU, and thus does not
readily disseminate in normal mice except at very high
doses [2] but was found in the liver and spleen of the
immunocompromised mice at a very low dose [1]. This
was not due to increased lung permeability by the
immunocompromise itself but was a result of both Cy
treatment and P. aeruginosa infection [1]. Similar dis-
semination from the gastrointestinal tract of P. aeruginosa
colonized mice was seen after Cy or RB6-8C5 treatment
[3]. This suggests that the combination of immunocom-
promise and P. aeruginosa promotes the dissemination
that is characteristic of this devastating infection in
patients undergoing chemotherapy.
While ExoU is apparently not required for infection in
immunocompromised hosts, P. aeruginosa strains that
express ExoU and the type III secretion system have been
associated with poor outcomes in patients with hospital-
acquired and ventilator-associated pneumonia [4-6]. In
fact, it has been shown recently that ExoU itself interferes
with the ability of recruited phagocytic cells to eradicate
bacteria from the lung, thus promoting additional
immunosuppression [7].
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with multiple P. aeruginosa strains in Cy- or RB6-8C5-
treated mice and observed the same increased suscept-
ibility. Reconstitution of neutrophils by recombinant
murine granulocyte colony-stimulating factor partially
restored host resistance to infection, implicating these
cells as critical immune effectors. MyD88
−/− mice, which
cannot recruit neutrophils to the lung, were also highly
susceptible to P. aeruginosa infection. Interestingly, mice
lacking functional lymphocytes (RAG
−/−) were only
slightly more susceptible to infection than wild-type
mice, but those depleted for resident alveolar macro-
phages did not show increased susceptibility. These
findings suggest that the recruitment of neutrophils to
the lung may be a reasonable approach to augment host
resistance to P. aeruginosa infections. Other studies
indicate that such recruitment must be carefully timed
with respect to the infection process as the effects of
neutrophils themselves can be detrimental if attuned
inappropriately [9].
Patients with CF are particularly susceptible to infections
with P. aeruginosa but are not generally considered
immunocompromised. While a defective CF transmem-
brane conductance regulator (CFTR) gene can affect
virtually all cell types, studies of neutrophils from
patients with CF continue to implicate these cells as
critical players in the susceptibility to chronic lung
infection by P. aeruginosa.
Dysregulation of various neutrophil functions in CF
results in decreased bacterial killing as well as persistent
neutrophil influx to the airways, leading to increased
lung damage (reviewed in [10-12]). It remains contro-
versial whether abnormalities exist in the oxidative
responses of these neutrophils compared with those
from healthy individuals [13]. Microarray analysis of
neutrophils from children with CF has indicated that
these cells show a distinctive pattern of gene expression
compared with cells from healthy young adults [14];
however, as none of the subjects in this study tested
positive for P. aeruginosa, the effects in the context of
infection were not considered.
Components of neutrophils can directly influence
P. aeruginosa infection. For example, CF neutrophils
secrete increased levels of neutrophil elastase (NE)
compared with cells from healthy subjects. While NE is
generally considered a contributor to tissue damage
associated with P. aeruginosa infection, neutrophils from
NE-deficient mice are less able to kill P. aeruginosa than
those from wild-type mice. Also, NE-deficient mice are
more susceptible to infection, and as this is not due to a
defect in recruitment, it suggests an important role for NE
in innate defense [15]. Similar effects were seen with
mice lacking the neutrophil serine protease inhibitor,
serpinb1, which dampens the activity of NE and other
proteases [16].
P. aeruginosa killing by neutrophils from normal donors
and CF patients was recently measured by Painter et al.
[17]. In addition to finding that CF neutrophils had a
significantly lower rate of killing, these authors went on to
show that inhibition of CFTR itself blocked P. aeruginosa
killing, implicating this protein as an important compo-
nent of neutrophil function.
Studies have shown that among the Toll-like receptors
(TLRs) tested, only TLR-5 is surface-expressed and
upregulated on the airway neutrophils of patients with
CF compared with those of healthy individuals [18].
TLR-5 is the cellular receptor for bacterial flagellin.
However, since chronic P. aeruginosa isolates from
patients with CF show decreased flagella expression
(one mechanism being the suppression of transcription
of flagellin by NE [19]), there is ligand-receptor
mismatch and therefore impaired neutrophil function
(reviewed in [20]). The importance of other TLRs in
neutrophil function and P. aeruginosa susceptibility has
not been as thoroughly investigated.
A recent study by Hartl et al. [21] (reviewed in [22])
showed that interleukin-8 (IL-8) binds to CXCR1, a G
protein-coupled chemokine receptor (also known as IL-
8RA), to promote PMN-mediated killing of P. aeruginosa.
However, CXCR1 on neutrophils from the airways of
patients with CF was found to be proteolytically cleaved.
This degraded receptor led to defects in the bactericidal
capacity of neutrophils. In addition, the cleaved receptor
fragments induced large amounts of IL-8 in the airways,
which recruited more neutrophils, setting up a vicious
cycle of airway inflammation in CF.
While numerous secreted and injected enzymes produced
by P. aeruginosa can affect epithelial and other cells
(reviewed in [23]), particular P. aeruginosa factors can
protect the bacterium from neutrophil-mediated killing.
While the polysaccharide alginate is well known for its
anti-phagocytic properties, P. aeruginosa rhamnolipids
have recently been shown to cause necrotic death of
PMNs, resulting in reduced clearance of the bacteria [24].
The expression of rhamnolipids is controlled through the
P. aeruginosa quorum-sensing system, and microarray
studies have revealed that this system is itself activated in
the presence of PMNs. Also, it was shown that biofilms
formed in the presence of PMNs produced more rhamno-
lipids [25]. Thus, P. aeruginosa can provide itself with a
protective shield from neutrophils (reviewed in [26]).
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lead to uncontrolled release of granule proteins, DNA,
and actin from necrotic cells. These latter two factors
have been shown to be important for biofilm develop-
ment [27-29]. These findings suggest that these compo-
nents could be important targets for anti-biofilm and
anti-Pseudomonal therapy (reviewed in [30]).
Future directions
It is now appreciated that P. aeruginosa strains with
distinct genotypes and phenotypes can be recognized in
the natural environment and different types of infections
[31-35]. In addition to recent P. aeruginosa transcriptome
analysis (reviewed in [36]) and metabolic pathway
studies [37], future investigations should be extended
to include multiple P. aeruginosa strains as well as
polymicrobial communities present in the environment
and in infection.
The natural and acquired antibiotic resistance of
P. aeruginosa makes infections by this bacterium extre-
mely difficult to treat, and thus the search is on to
identify mechanisms or molecules to increase sensitivity
to antibiotics [38]. Also, there is a push to find inhibitors
of the synthesis or regulation (or both) of factors critical
for virulence.
It is a breakdown in the normal host response that is
responsible for most of the susceptibility to infection with
this bacterium. While the importance of alveolar macro-
phages and other cells remains controversial [39], the
presence of neutrophils is required for protection from
infection. However, the appropriate regulation of neutro-
phil function is critical for a productive response. Studies
of neutrophils from CF and other immunodeficient
patientshavebeguntodefinethepathwaysandmolecules
critical for an effective innate immune response. These
studies have also shown that that there is a delicate
interplay between P. aeruginosa and the host to resolve an
infection. To define these interactions in more detail,
microarray studies have been performed on neutrophils
from animals infected with P. aeruginosa [40]. Future
investigations using human neutrophils [41] in the
context of P. aeruginosa infection could be even more
informative. Such studies may help identify mechanisms
to promote a more effective innate host response in
susceptible individuals and therefore provide protection
from infections by this important pathogen.
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